secwatch.observer — SEC 8-K summary
======================================

Issuer:     BullFrog AI Holdings, Inc. (BFRG)
CIK:        0001829247
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001493152-23-025446
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BullFrog AI announces USPTO issuance of patent for novel mebendazole prodrugs for cancer treatment
--------------------------------------------------------------------------------

- USPTO to issue Patent No. 11,712,435 on Aug 1, 2023, protecting novel prodrugs of mebendazole with improved solubility and oral bioavailability.
- This is the first patent from IP licensed from Johns Hopkins University in Oct 2022; BullFrog AI holds exclusive worldwide royalty-bearing rights.
- CEO Vin Singh says prodrugs address key difficulty in evaluating mebendazole for oncology, enhancing potential for glioblastoma and other cancers.
- Company intends to work with strategic partners to monetize the asset for clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829247/000149315223025446/0001493152-23-025446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829247/000149315223025446/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-025446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer